Dashboard
1
Poor Management Efficiency with a low ROCE of 3.39%
- The company has been able to generate a Return on Capital Employed (avg) of 3.39% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 3.63% and Operating profit at 5.08% over the last 5 years
3
Flat results in Jun 25
4
With ROE of 5.78%, it has a very expensive valuation with a 5.70 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,333 Million (Mid Cap)
99.00
NA
0.00%
-0.16
5.78%
5.70
Revenue and Profits:
Net Sales:
353 Million
(Quarterly Results - Jun 2025)
Net Profit:
14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.48%
0%
9.48%
6 Months
-3.69%
0%
-3.69%
1 Year
-13.83%
0%
-13.83%
2 Years
-47.64%
0%
-47.64%
3 Years
-35.93%
0%
-35.93%
4 Years
-20.25%
0%
-20.25%
5 Years
33.1%
0%
33.1%
GuangYuYuan Chinese Herbal Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.63%
EBIT Growth (5y)
5.08%
EBIT to Interest (avg)
-0.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.68
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.39%
ROE (avg)
3.01%
Valuation key factors
Factor
Value
P/E Ratio
99
Industry P/E
Price to Book Value
5.70
EV to EBIT
101.00
EV to EBITDA
68.50
EV to Capital Employed
6.57
EV to Sales
6.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.50%
ROE (Latest)
5.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
352.70
408.20
-13.60%
Operating Profit (PBDIT) excl Other Income
22.70
67.00
-66.12%
Interest
0.70
0.70
Exceptional Items
0.00
0.00
Consolidate Net Profit
14.00
65.60
-78.66%
Operating Profit Margin (Excl OI)
29.70%
164.10%
-13.44%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -13.60% vs 28.81% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -78.66% vs 1,887.88% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,189.20
1,252.30
-5.04%
Operating Profit (PBDIT) excl Other Income
144.00
153.60
-6.25%
Interest
7.90
17.10
-53.80%
Exceptional Items
-4.70
-0.00
Consolidate Net Profit
83.60
92.90
-10.01%
Operating Profit Margin (Excl OI)
75.50%
89.20%
-1.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -5.04% vs 12.80% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -10.01% vs 135.32% in Dec 2023
About GuangYuYuan Chinese Herbal Medicine Co., Ltd. 
GuangYuYuan Chinese Herbal Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






